1. Medtech Insight
  2. >>Policy & Regulation
  3. >>Regulation

FDA Brain Simulator Will Allow Evaluation Of Electrostimulation Devices On Human Nerve Cells

FDA's device center is developing computational models of the human brain to help regulators and device designers assess the physiological effects of electromagnetic fields – such as those generated by implanted nerve stimulators – on the nervous system.

With contractor proposals in hand, FDA is poised to pick a computational model simulating the brain’s reaction to electromagnetic fields. The agency's device center expects the model to help pre-market reviewers quickly assess the safety and efficacy of implanted nerve stimulators, transcranial magnetic stimulators and magnetic resonance imaging devices.

The model should also prove useful to researchers and manufacturers, as the agency plans to make it available to the...

Welcome to Medtech Insight

Create an account to read this article

Already a subscriber?

More from Regulation

FDA Commissioner’s Voucher Program Should Include Devices, Transplant Technology Firm Says

 
• By Elizabeth Orr

The FDA's new Commissioner’s National Priority Voucher program aims to expedite drug approvals significantly. Device firms like XVIVO advocate for a similar initiative for devices, emphasizing the potential for faster reviews and improved patient access to lifesaving technologies.

HealthAI: ‘Established Regulations Already Exist For Regulating AI In Healthcare Safely’

 
• By Natasha Barrow

Paul Campbell, chief regulatory officer at HealthAI, emphasizes existing regulations for AI in healthcare should not be overlooked as new regulations are developed.

EUDAMED Notice Anticipated By September As Commission Optimizes Operations

 
• By Amanda Maxwell

The last steps are taking place leading to the launch of the EU’s medical device database, EUDAMED.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.

More from Policy & Regulation

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 
• By Malcolm Spicer

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 
• By Brian Bossetta

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 
• By Amanda Maxwell

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.